tetano
Editor, Senior Moderator
Nephron
. 2020 Dec 8;1-7.
doi: 10.1159/000512329. Online ahead of print.
COVID-19 in Renal Transplant Recipients: Case Series and a Brief Review of Current Evidence
Muhammed Ahmed Elhadedy[SUP] 1 2 [/SUP], Yazin Marie[SUP] 1 [/SUP], Ahmed Halawa[SUP] 3 4 [/SUP]
Affiliations
Abstract
By April 26, 2020, infections related to coronavirus disease 2019 (COVID-19) affected people from 210 countries and caused 203,818 reported deaths worldwide. A few studies discussed the outcome of COVID-19 in kidney transplant recipients. This short series demonstrates our experience in managing COVID-19 disease in renal transplant patients in the absence of strong evidence. We report 8 cases of kidney transplant recipients infected with COVID-19 (median age = 48.5 years; range = 21-71 years), including 4 males and 4 females. The most frequently associated comorbidity was hypertension. The most common presenting features were fever and cough. The main radiological investigation was a portable chest X-ray. Other common features included lymphopenia, high C-reactive protein, and a very high ferritin level. Overall, 1 patient was managed as an outpatient, the remaining 7 required hospital admission, 1 of them referred to the intensive therapy unit. Management included supportive treatment (intravenous fluid therapy, monitoring renal function, and symptomatic treatment with or without ward-based oxygen therapy depending on oxygen saturation) and discontinuation of the antiproliferative immunosuppressive drugs. Seven patients recovered and discharged home to self-isolate. One patient required intensive care treatment and mechanical ventilation. Supportive treatment could be sufficient for the management or to be tried first. We also found that short hospital stay with self-isolation on discharge reduces the burden on the health service and protect the staff and the public.
Keywords: Coronavirus disease 2019; Immunosuppression; Kidney transplantation.
. 2020 Dec 8;1-7.
doi: 10.1159/000512329. Online ahead of print.
COVID-19 in Renal Transplant Recipients: Case Series and a Brief Review of Current Evidence
Muhammed Ahmed Elhadedy[SUP] 1 2 [/SUP], Yazin Marie[SUP] 1 [/SUP], Ahmed Halawa[SUP] 3 4 [/SUP]
Affiliations
- PMID: 33291120
- DOI: 10.1159/000512329
Abstract
By April 26, 2020, infections related to coronavirus disease 2019 (COVID-19) affected people from 210 countries and caused 203,818 reported deaths worldwide. A few studies discussed the outcome of COVID-19 in kidney transplant recipients. This short series demonstrates our experience in managing COVID-19 disease in renal transplant patients in the absence of strong evidence. We report 8 cases of kidney transplant recipients infected with COVID-19 (median age = 48.5 years; range = 21-71 years), including 4 males and 4 females. The most frequently associated comorbidity was hypertension. The most common presenting features were fever and cough. The main radiological investigation was a portable chest X-ray. Other common features included lymphopenia, high C-reactive protein, and a very high ferritin level. Overall, 1 patient was managed as an outpatient, the remaining 7 required hospital admission, 1 of them referred to the intensive therapy unit. Management included supportive treatment (intravenous fluid therapy, monitoring renal function, and symptomatic treatment with or without ward-based oxygen therapy depending on oxygen saturation) and discontinuation of the antiproliferative immunosuppressive drugs. Seven patients recovered and discharged home to self-isolate. One patient required intensive care treatment and mechanical ventilation. Supportive treatment could be sufficient for the management or to be tried first. We also found that short hospital stay with self-isolation on discharge reduces the burden on the health service and protect the staff and the public.
Keywords: Coronavirus disease 2019; Immunosuppression; Kidney transplantation.